Literature DB >> 23846294

Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy.

Michael Lee1, H Richard Alexander, Allen Burke.   

Abstract

BACKGROUND: Diffuse peritoneal mesothelioma (DPM) forms a spectrum of indolent surface tumours to malignant invasive cancers. There are few pathological series that span well and poorly differentiated lesions that show diffuse peritoneal spread.
METHODS: Sixty-four DPM treated by initial cytoreductive therapy were retrospectively reviewed. Tumours were classified by surface and invasive growth pattern and correlated with risk factors, peritoneal cancer index (PCI) and completeness of cytoreduction (CCR). Degree of invasion was quantitated as absent (0), into stroma (I), into fat (II), and into adjacent structures (III) and was correlated with cytological features. Selected immunohistochemical stains were performed.
RESULTS: There were three well differentiated papillary mesotheliomas (WDPM; type A), four multicystic mesothelioma (type B), 22 tubulopapillary epithelioid mesotheliomas (type C), and 35 poorly differentiated epithelioid mesotheliomas with solid or sarcomatoid growth (Type D). Seven type D tumours had prominent sarcomatoid areas, 12 deciduoid areas, and four lymphohistiocytoid features. Risk factors were present in all groups except type A, and included prior abdominal surgery (n=24), asbestos exposure (n=5) and radiation (n=2). Extra-pleural mesothelioma was present in all groups except type B (total n=7, 11%). Two type A and eight type C tumours lacked invasion; only type D showed level III invasion. The invasive portion of one type A tumour and two type B tumours showed adenomatoid features. PCI and CCR were greater in type D compared to the other groups (p=0.02), as well as mitotic rate, degree of necrosis, and nuclear pleomorphism (p<0.001). Degree of invasion was strongly correlated with CCR (p=0.007), necrosis (p<0.0001), nuclear grade (p<0.0001), and mitotic rate (p=0.001), but not PCI (p=0.1). Immunohistochemical results were similar across groups, with frequent positivity for CA125 (94%), EGFR (94%) and calretinin (93%), followed by p16 (85%), cytokeratin 5,6 (76%), D2-40 (71%) and WT-1 (47%). PAX-8 was negative in all tumours, except one type A tumour that showed diffuse nuclear positivity.
CONCLUSIONS: Diffuse peritoneal mesotheliomas can be classified into four groups that reflect invasive potential, degree of adverse histological features, and amenability for CCR. Non-invasive tumours include both type A and type C tumours.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23846294     DOI: 10.1097/PAT.0b013e3283631cce

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  15 in total

Review 1.  Malignant peritoneal mesothelioma: a review.

Authors:  Joseph Kim; Shanel Bhagwandin; Daniel M Labow
Journal:  Ann Transl Med       Date:  2017-06

2.  A Rare Complication of Diffuse Malignant Peritoneal Mesothelioma: Spontaneous Ileal Perforation.

Authors:  Orhan Kalaycı; Güven Barış Cansu; Bengür Taşkıran; Özlem Eren
Journal:  Indian J Surg Oncol       Date:  2019-04-06

Review 3.  Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Authors:  Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass
Journal:  CA Cancer J Clin       Date:  2019-07-08       Impact factor: 508.702

4.  Association of Asbestos Exposure With Malignant Mesothelioma Incidence in Eastern China.

Authors:  Weimin Mao; Xing Zhang; Zhenying Guo; Zhibin Gao; Harvey I Pass; Haining Yang; Michele Carbone
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

5.  A case of malignant peritoneal mesothelioma suggesting the utility of combining double-contrast radiography and endoscopy with computed tomography for diagnosis.

Authors:  Hirokazu Saito; Shota Hasuda; Jiro Nasu; Mitsuhiko Kitaoka; Ikuo Matsushita
Journal:  Clin J Gastroenterol       Date:  2017-06-23

6.  Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Authors:  Miklos Acs; Michael Gerken; Ivana Gajic; Max Mayr; Jozef Zustin; Pompiliu Piso
Journal:  Langenbecks Arch Surg       Date:  2022-06-23       Impact factor: 3.445

7.  Nivolumab-induced peritonitis with peritoneal mesothelial hyperplasia mimicking metastatic mesothelioma.

Authors:  Allen Burke; Teklu Legesse
Journal:  AJSP Rev Rep       Date:  2022 May-Jun

Review 8.  Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Authors:  Angela Bononi; Andrea Napolitano; Harvey I Pass; Haining Yang; Michele Carbone
Journal:  Expert Rev Respir Med       Date:  2015-08-26       Impact factor: 3.772

Review 9.  Diagnosis and management of patients with malignant peritoneal mesothelioma.

Authors:  H Richard Alexander; Allen P Burke
Journal:  J Gastrointest Oncol       Date:  2016-02

Review 10.  The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies.

Authors:  Mackenzie C Morris; Jordan M Cloyd; John Hays; Sameer H Patel
Journal:  J Gastrointest Surg       Date:  2020-08-17       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.